Benitec Biopharma (BNTC) News Today $13.68 +0.41 (+3.09%) Closing price 04:00 PM EasternExtended Trading$13.71 +0.03 (+0.22%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Benitec Biopharma (NASDAQ:BNTC) Stock Price Expected to Rise, JMP Securities Analyst SaysApril 13 at 3:25 AM | americanbankingnews.comBenitec Biopharma Inc. (NASDAQ:BNTC) Receives $24.43 Average PT from BrokeragesApril 12 at 2:05 AM | americanbankingnews.comBenitec Biopharma price target raised to $20 from $18 at Citizens JMPApril 12 at 12:58 AM | markets.businessinsider.comBenitec Biopharma Inc. (NASDAQ:BNTC) Given Average Rating of "Buy" by BrokeragesShares of Benitec Biopharma Inc. (NASDAQ:BNTC - Get Free Report) have been given an average rating of "Buy" by the nine ratings firms that are covering the company, MarketBeat.com reports. Seven equities research analysts have rated the stock with a buy rating and two have issued a strong buy ratiApril 10, 2025 | marketbeat.comBenitec Biopharma participates in a conference call with Cantor FitzgeraldApril 8, 2025 | markets.businessinsider.comFranklin Resources Inc. Raises Stock Position in Benitec Biopharma Inc. (NASDAQ:BNTC)Franklin Resources Inc. grew its holdings in Benitec Biopharma Inc. (NASDAQ:BNTC - Free Report) by 269.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,939,287 shares of the biotechnology compaApril 7, 2025 | marketbeat.comLeerink Partnrs Issues Positive Estimate for BNTC EarningsBenitec Biopharma Inc. (NASDAQ:BNTC - Free Report) - Investment analysts at Leerink Partnrs raised their Q3 2025 earnings estimates for Benitec Biopharma in a research report issued on Monday, March 31st. Leerink Partnrs analyst M. Foroohar now expects that the biotechnology company will earn ($0April 5, 2025 | marketbeat.comInsiders Are Loving These 5 Tech and Biotech StocksApril 2, 2025 | 247wallst.comBenitec Biopharma Inc. (NASDAQ:BNTC) Short Interest Up 23.6% in MarchBenitec Biopharma Inc. (NASDAQ:BNTC - Get Free Report) saw a large increase in short interest in March. As of March 15th, there was short interest totalling 216,100 shares, an increase of 23.6% from the February 28th total of 174,800 shares. Based on an average trading volume of 50,800 shares, the days-to-cover ratio is presently 4.3 days. Approximately 0.9% of the shares of the stock are short sold.April 2, 2025 | marketbeat.comBenitec Biopharma completes stock and warrant offeringsMarch 30, 2025 | investing.comSuvretta Capital Management, L Acquires 900,000 Shares of Benitec Biopharma Inc. (NASDAQ:BNTC) StockBenitec Biopharma Inc. (NASDAQ:BNTC - Get Free Report) Director Suvretta Capital Management, L purchased 900,000 shares of the stock in a transaction that occurred on Wednesday, March 26th. The stock was bought at an average cost of $13.00 per share, with a total value of $11,700,000.00. Following the completion of the transaction, the director now directly owns 8,793,245 shares in the company, valued at $114,312,185. The trade was a 11.40 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.March 29, 2025 | marketbeat.comBenitec Biopharma inks deal granting stock resale rightsMarch 29, 2025 | investing.comInsider Buying: Benitec Biopharma Inc. (NASDAQ:BNTC) Director Buys 900,000 Shares of StockMarch 29, 2025 | insidertrades.comPiper Sandler Keeps Their Buy Rating on Benitec Biopharma (BNTC)March 28, 2025 | markets.businessinsider.comBenitec Biopharma prices 1.44M shares at $13.00 in underwritten offeringMarch 27, 2025 | markets.businessinsider.comBenitec Biopharma prices $30M securities offeringsMarch 25, 2025 | msn.comBenitec Biopharma's (BNTC) Buy Rating Reiterated at HC WainwrightHC Wainwright restated a "buy" rating and set a $28.00 price objective on shares of Benitec Biopharma in a research report on Monday.March 25, 2025 | marketbeat.comBenitec Biopharma Inc. Announces Pricing of $30 Million Common Stock OfferingMarch 25, 2025 | globenewswire.comSimplify Asset Management Inc. Trims Stake in Benitec Biopharma Inc. (NASDAQ:BNTC)Simplify Asset Management Inc. lessened its position in shares of Benitec Biopharma Inc. (NASDAQ:BNTC - Free Report) by 34.5% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 76,337 shares of the biotechnology company's stoMarch 24, 2025 | marketbeat.comBenitec Biopharma Reports Positive Interim Results For BB-301 Gene Therapy In OPMD Clinical TrialMarch 22, 2025 | nasdaq.comBenitec Biopharma Inc. (NASDAQ:BNTC) Short Interest Up 17.6% in FebruaryBenitec Biopharma Inc. (NASDAQ:BNTC - Get Free Report) saw a significant increase in short interest in the month of February. As of February 28th, there was short interest totalling 174,800 shares, an increase of 17.6% from the February 13th total of 148,700 shares. Currently, 0.8% of the shares of the company are short sold. Based on an average trading volume of 49,700 shares, the days-to-cover ratio is currently 3.5 days.March 20, 2025 | marketbeat.comBenitec Biopharma Inc. (NASDAQ:BNTC) Receives Consensus Recommendation of "Buy" from AnalystsBenitec Biopharma Inc. (NASDAQ:BNTC - Get Free Report) has earned an average recommendation of "Buy" from the nine brokerages that are presently covering the stock, MarketBeat reports. Seven research analysts have rated the stock with a buy recommendation and two have assigned a strong buy recommeMarch 15, 2025 | marketbeat.comBenitec - Another Biopharma RocketMarch 13, 2025 | talkmarkets.comBenitec Biopharma (NASDAQ:BNTC) Shares Cross Above 50-Day Moving Average - Here's WhyBenitec Biopharma (NASDAQ:BNTC) Shares Cross Above 50-Day Moving Average - What's Next?March 12, 2025 | marketbeat.comBenitec Biopharma (NASDAQ:BNTC) Share Price Passes Above Fifty Day Moving Average - Here's What HappenedBenitec Biopharma (NASDAQ:BNTC) Shares Cross Above 50-Day Moving Average - Here's WhyMarch 4, 2025 | marketbeat.comBenitec Biopharma to Participate in Upcoming Conferences in MarchFebruary 26, 2025 | markets.businessinsider.comPiper Sandler Sticks to Their Buy Rating for Benitec Biopharma (BNTC)February 26, 2025 | markets.businessinsider.comHC Wainwright Reiterates "Buy" Rating for Benitec Biopharma (NASDAQ:BNTC)HC Wainwright restated a "buy" rating and set a $28.00 target price on shares of Benitec Biopharma in a report on Friday.February 22, 2025 | marketbeat.comAnalysts Are Bullish on These Healthcare Stocks: Benitec Biopharma (BNTC), Halozyme (HALO)February 19, 2025 | markets.businessinsider.comBenitec Biopharma Inc. (NASDAQ:BNTC) Receives Consensus Rating of "Buy" from AnalystsShares of Benitec Biopharma Inc. (NASDAQ:BNTC - Get Free Report) have received an average recommendation of "Buy" from the nine ratings firms that are currently covering the company, MarketBeat Ratings reports. Seven investment analysts have rated the stock with a buy recommendation and two have giFebruary 18, 2025 | marketbeat.comBenitec Biopharma (NASDAQ:BNTC) Posts Earnings Results, Beats Expectations By $0.19 EPSBenitec Biopharma (NASDAQ:BNTC - Get Free Report) issued its quarterly earnings results on Friday. The biotechnology company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($0.55) by $0.19.February 15, 2025 | marketbeat.comBenitec Biopharma reports Q2 EPS (33c) vs ($2.64) last yearFebruary 15, 2025 | markets.businessinsider.comBenitec presents new gene therapy data at MD conferenceFebruary 14, 2025 | msn.comBenitec Biopharma Releases Second Quarter 2025 Financial Results and Provides Operational UpdateFebruary 14, 2025 | globenewswire.comBenitec Biopharma (NASDAQ:BNTC) Shares Pass Below 50-Day Moving Average - Here's WhyBenitec Biopharma (NASDAQ:BNTC) Share Price Passes Below Fifty Day Moving Average - Here's What HappenedFebruary 13, 2025 | marketbeat.comBenitec Biopharma (BNTC) to Release Quarterly Earnings on MondayBenitec Biopharma (NASDAQ:BNTC) will be releasing earnings on Monday, February 10, Financial Modeling Prep reports.February 3, 2025 | marketbeat.comBenitec Biopharma (NASDAQ:BNTC) Shares Pass Above 50 Day Moving Average - Here's What HappenedBenitec Biopharma (NASDAQ:BNTC) Stock Crosses Above 50 Day Moving Average - Here's WhyFebruary 1, 2025 | marketbeat.comFranklin Resources Inc. Acquires Significant Stake in Benitec Biopharma Inc.January 27, 2025 | gurufocus.comBenitec Biopharma to Participate in Upcoming Conferences in January and FebruaryJanuary 27, 2025 | markets.businessinsider.comBenitec Biopharma: Early Positive Data, Small Target Market, Little CompetitionJanuary 20, 2025 | seekingalpha.comBenitec Biopharma Inc. (NASDAQ:BNTC) Short Interest UpdateBenitec Biopharma Inc. (NASDAQ:BNTC - Get Free Report) saw a significant growth in short interest in December. As of December 31st, there was short interest totalling 62,300 shares, a growth of 65.7% from the December 15th total of 37,600 shares. Based on an average daily trading volume, of 55,200 shares, the short-interest ratio is presently 1.1 days.January 15, 2025 | marketbeat.comBenitec Biopharma (NASDAQ:BNTC) Stock Crosses Below Fifty Day Moving Average - Should You Sell?Benitec Biopharma (NASDAQ:BNTC) Stock Passes Below Fifty Day Moving Average - Here's What HappenedJanuary 9, 2025 | marketbeat.comBenitec Biopharma Inc. (NASDAQ:BNTC) Receives Average Rating of "Buy" from AnalystsBenitec Biopharma Inc. (NASDAQ:BNTC - Get Free Report) has earned a consensus rating of "Buy" from the nine analysts that are presently covering the company, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a buy recommendation and two have assigned a strong bDecember 30, 2024 | marketbeat.comBenitec Biopharma Inc. (NASDAQ:BNTC) Director Suvretta Capital Management, L Acquires 27,502 SharesDecember 27, 2024 | insidertrades.comBenitec Biopharma Inc. (NASDAQ:BNTC) Director Buys $301,971.96 in StockBenitec Biopharma Inc. (NASDAQ:BNTC - Get Free Report) Director Suvretta Capital Management, L purchased 27,502 shares of the firm's stock in a transaction on Monday, December 23rd. The stock was bought at an average price of $10.98 per share, with a total value of $301,971.96. Following the acquisition, the director now owns 7,981,725 shares in the company, valued at $87,639,340.50. This trade represents a 0.35 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.December 26, 2024 | marketbeat.comWhat is HC Wainwright's Estimate for BNTC Q2 Earnings?Benitec Biopharma Inc. (NASDAQ:BNTC - Free Report) - HC Wainwright issued their Q2 2025 EPS estimates for Benitec Biopharma in a research report issued on Monday, December 16th. HC Wainwright analyst R. Selvaraju anticipates that the biotechnology company will earn ($0.27) per share for the quartDecember 19, 2024 | marketbeat.comHedge funds investors own a significant stake of 38% in Benitec Biopharma Inc. (NASDAQ:BNTC)December 18, 2024 | finance.yahoo.comBenitec Biopharma (NASDAQ:BNTC) Earns Buy Rating from Analysts at HC WainwrightHC Wainwright started coverage on Benitec Biopharma in a report on Monday. They issued a "buy" rating and a $28.00 price target for the company.December 16, 2024 | marketbeat.comBenitec Biopharma (NASDAQ:BNTC) Coverage Initiated by Analysts at HC WainwrightHC Wainwright started coverage on Benitec Biopharma in a research report on Monday. They set a "buy" rating and a $28.00 price objective for the company.December 16, 2024 | marketbeat.comShort Interest in Benitec Biopharma Inc. (NASDAQ:BNTC) Grows By 6.9%Benitec Biopharma Inc. (NASDAQ:BNTC - Get Free Report) was the target of a large increase in short interest in November. As of November 30th, there was short interest totalling 35,400 shares, an increase of 6.9% from the November 15th total of 33,100 shares. Based on an average daily volume of 39,100 shares, the days-to-cover ratio is presently 0.9 days.December 15, 2024 | marketbeat.com Remove Ads Get Benitec Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for BNTC and its competitors with MarketBeat's FREE daily newsletter. Email Address BNTC Media Mentions By Week BNTC Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BNTC News Sentiment▼0.620.80▲Average Medical News Sentiment BNTC News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BNTC Articles This Week▼72▲BNTC Articles Average Week Remove Ads Get Benitec Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for BNTC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies OCUL News CALT News EVO News AMPH News ADPT News IOVA News ARDX News GPCR News AUPH News SNDX News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BNTC) was last updated on 4/15/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Benitec Biopharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Benitec Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
